Use of second generation H1 antihistamines in special situations. 2013

I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero

Antihistamine drugs are one of the therapeutic classes most used at world level, at all ages and in multiple situations. Although in general they have a good safety profile, only the more recent drugs (second generation antihistamines) have been studied specifically with regard to the more important safety aspects. Given the variety of antihistamine drugs, they cannot all be considered equivalent in application to various special clinical situations, so that the documented clinical experience must be assessed in each case or, in the absence of such, the particular pharmacological characteristics of each molecule for the purpose of recommendation in these special situations. In general, there are few clinical studies published for groups of patients with kidney or liver failure, with concomitant multiple pathologies (such as cardiac pathology), in extremes of age (paediatrics or geriatrics) and in natural stages such as pregnancy or lactation, but these are normal situations and it is more and more frequent (among the elderly) for antihistamine drugs to be recommended. This review sets out the more relevant details compiled on the use of antihistamines in these special situations.

UI MeSH Term Description Entries
D001942 Breast Feeding The nursing of an infant at the breast. Breast Fed,Breastfed,Milk Sharing,Wet Nursing,Breast Feeding, Exclusive,Breastfeeding,Breastfeeding, Exclusive,Exclusive Breast Feeding,Exclusive Breastfeeding,Sharing, Milk
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017093 Liver Failure Severe inability of the LIVER to perform its normal metabolic functions, as evidenced by severe JAUNDICE and abnormal serum levels of AMMONIA; BILIRUBIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; LACTATE DEHYDROGENASES; and albumin/globulin ratio. (Blakiston's Gould Medical Dictionary, 4th ed) Hepatic Failure
D051437 Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. Kidney Insufficiency,Kidney Failure,Renal Failure,Failure, Kidney,Failure, Renal,Failures, Kidney,Failures, Renal,Insufficiency, Kidney,Kidney Failures,Kidney Insufficiencies,Renal Failures,Renal Insufficiencies
D039563 Histamine H1 Antagonists, Non-Sedating A class of non-sedating drugs that bind to but do not activate histamine receptors (DRUG INVERSE AGONISM), thereby blocking the actions of histamine or histamine agonists. These antihistamines represent a heterogenous group of compounds with differing chemical structures, adverse effects, distribution, and metabolism. Compared to the early (first generation) antihistamines, these non-sedating antihistamines have greater receptor specificity, lower penetration of BLOOD-BRAIN BARRIER, and are less likely to cause drowsiness or psychomotor impairment. Second Generation Antihistamine,Second Generation H1 Antagonist,Third Generation H1 Antagonist,H1 Antihistamines, Non-Sedating,Second Generation Antihistamines,Second Generation H1 Antagonists,Third Generation H1 Antagonists,Antihistamine, Second Generation,Antihistamines, Second Generation,Generation Antihistamine, Second,H1 Antihistamines, Non Sedating,Histamine H1 Antagonists, Non Sedating,Non-Sedating H1 Antihistamines

Related Publications

I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
January 2000, Allergy,
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
May 1998, International journal of clinical pharmacology and therapeutics,
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
February 1992, Annals of allergy,
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
September 2005, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
September 2016, American family physician,
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
October 2015, European journal of pharmacology,
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
October 2001, Pharmacology & toxicology,
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
May 2000, Cleveland Clinic journal of medicine,
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
December 2011, American journal of clinical dermatology,
I Dávila, and A del Cuvillo, and J Mullol, and I Jáuregui, and J Bartra, and M Ferrer, and J Montoro, and J Sastre, and A Valero
June 1999, International journal of clinical pharmacology and therapeutics,
Copied contents to your clipboard!